Day: April 8, 2020

SOUTH SAN FRANCISCO, Calif., April 08, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today announced preliminary unaudited revenue for the three months ended March 31, 2020 and withdrew its previously issued full year 2020 revenue guidance.First Quarter RevenuePreliminary revenue for the three months ended March 31, 2020 is expected to be $38.3 million, an increase of 47% compared with $26.0 million in the first quarter of 2019. In the quarter, the Company provided approximately 15,000 patient results, increasing 50% year-over-year. The preliminary information presented in this press release is based on CareDx’s current expectations...

Dorman facilities and global supply chain continue to meet current customer demand levelsProactive steps taken to manage costs, enhance liquidity and bolster balance sheetGiven uncertainty of COVID-19 pandemic, Dorman withdraws fiscal 2020 guidanceDorman announces it will report first quarter 2020 financial results on April 27, 20202020 Annual Meeting of Shareholders to be held virtuallyCOLMAR, Pa., April 08, 2020 (GLOBE NEWSWIRE) — Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ:DORM), a leading supplier in the automotive aftermarket industry, today provided an update on its business operations in light of the ongoing Coronavirus (COVID-19) pandemic.“First and foremost, the health and safety of our employees, customers, and suppliers remain our utmost priority,” said Kevin Olsen, President and Chief Executive Officer...

SOUTH SAN FRANCISCO, Calif., April 08, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, at 10:40 AM EST.Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.About CytokineticsCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class...

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Altus Group Limited (“Altus Group” or “the Company”) (TSX: AIF) announced today that it plans to release its first quarter results for the period ended March 31, 2020 after market close on Thursday, May 7, 2020. Altus Group executives Robert Courteau, Chief Executive Officer, and Angelo Bartolini, Chief Financial Officer, will host a conference call and webcast at 5:00 p.m. (ET) the same day to review the financial results and discuss corporate developments.Q1 2020 Results Conference Call & WebcastAbout Altus Group LimitedAltus Group Limited is a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry. Our businesses, Altus Analytics and Altus Expert Services, reflect decades of experience, a range of expertise, and...

Pratteln, Switzerland, April 8, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that the number of its shares recorded in the commercial register has been increased from 11,164,563 shares by 1,150,000 shares to 12,314,563 shares.On April 8, 2020, 1,150,000 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares under the equity-linked financing provided by IRIS announced earlier today.About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage or age....

Pratteln, Schweiz, 8. April 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass die Anzahl der im Handelsregister eingetragenen Aktien von 11‘164‘563 Aktien um 1‘150‘000 Aktien auf 12‘314‘563 Aktien erhöht wurde.Am 8. April 2020 wurden aus dem genehmigten Kapital 1‘150‘000 neue eigene Aktien geschaffen. Santhera erwartet, diese unter der aktiengebundenen Finanzierungsvereinbarung mit IRIS gemäss der Pressemitteilung von heute morgen zu verwenden.Über SantheraSanthera Pharmaceuticals (SIX: SANN), ein Schweizer Spezialitätenpharmaunternehmen, ist auf die Entwicklung und Vermarktung innovativer Medikamente für seltene neuromuskuläre und pulmonale Erkrankungen mit hohem medizinischem Bedarf fokussiert. Santhera baut ein Duchenne-Muskeldystrophie (DMD) Produktportfolio auf zur Behandlung von Patienten unabhängig von ursächlichen...

AS Merko Ehitus consolidated audited financial results for 2019 remain unchanged compared to the preliminary disclosure on 13 February 2020.STATEMENT OF THE CHAIRMAN OF THE MANAGEMENT BOARDDevelopments on the Baltic construction and real estate market continued as we expected in 2019. The rapid growth in construction volumes in recent years stabilized and developers have become more cautious in launching new real estate investments. Although state investments into infrastructure remained at the same level as in years past, the share of the public sector orders on the construction market has grown.The decrease in Merko Group’s construction volumes, by more than 20% compared to the record level of 2018, was also expected. The group’s sales revenue decreased year-over-year in Estonia and Latvia but remained at the same level in Lithuania...

ASi Merko Ehitus 2019. majandusaasta konsolideeritud auditeeritud finantstulemused ei ole võrreldes 13. veebruaril 2020 avaldatud esialgsete tulemustega muutunud.JUHATUSE ESIMEHE PÖÖRDUMINE

MONTREAL, April 08, 2020 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company will be presenting at the Mi3 Investor and Broker Video Conference this Friday April 10th at 1:30PM Eastern Time.The investor webinar will discuss the company’s newly launched products and markets relating to the Bioganix® CleanCare offering, including hand sanitizers and new residential in-home care systems. The company will also cover some recent developments and as well to discuss what is in store for shareholders in the coming period leading into summer.Investors interested in attending the webinar on April 10th at 1:30 EST may do so through the zoom portal using the link below:Video conference: https://zoom.us/j/652484090About Relevium...

CHICAGO, April 08, 2020 (GLOBE NEWSWIRE) — Cosmos Holdings, Inc. (“the Company”) (OTCQB: COSM), an international pharmaceutical company, announced today that it has signed a definitive agreement with SunMed Biosciences Limited to be the exclusive representative and distribution agent of a rapid Diagnostic Detection Kit (DDK) into four EU countries: Germany, England, Greece and Cyprus. Specifically, this product is used for qualitative detection of the presence of IgM and/or IgG antibody to SARS-CoV-2, virus that causes COVID-19, in human serum, plasma and whole blood.The Company looks forward to contributing in the fight against coronavirus utilizing its channels of distribution in the aforementioned geographic territories adding the DDK device to its portfolio of medical products for the protection and betterment of...